Reddy博士同意出售癌症药物HLX15 一种类似生物,在43个国家,包括美国,根据与Henlius的交易。 Dr. Reddy's agrees to sell cancer drug HLX15, a biosimilar, in 43 countries, including the U.S., under a deal with Henlius.

Reddy博士的实验室与上海Henlius生物科技签订了一项许可证协议,将HLX15商业化。 HLX15是美国和欧洲等43个国家用于治疗多种骨髓瘤的沙拉图玛布的生物类似物。 Dr. Reddy's Laboratories has entered into a licensing agreement with Shanghai Henlius Biotech to commercialize HLX15, a biosimilar of daratumumab used for treating multiple myeloma, in 43 countries including the U.S. and Europe. Henlius将处理发展、制造和供应问题,可能支付高达1.316亿美元。 Henlius will handle development, manufacturing, and supply, with potential payments up to $131.6 million. 这项交易旨在扩大这些市场上接受这种癌症治疗的机会。 The deal aims to expand access to this cancer treatment in these markets.